EI
COGT icon

EAM Investors’s Cogent Biosciences COGT Stock Holding History

EAM Investors’s Portfolio COGT Stock Details COGT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.06M Sell
53,129
-68,799
-56% -$2.41M 0.18% 174
2026
Q1 		$4.69M Sell
121,928
-12,367
-9% -$457K 0.54% 62
2025
Q4 		$4.77M Buy
+134,295
New +$3.78M 0.53% 80
2022
Q4 		– Sell
-337,777
Closed -$5.04M – 272
2022
Q3 		$5.04M Sell
337,777
-27,890
-8% -$382K 1.1% 3
2022
Q2 		$3.3M Buy
+365,667
New +$2.5M 0.81% 11

Other funds holding COGT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

EAM Investors's COGT Position: Q2 2026 in Review

EAM Investors reduced its Cogent Biosciences (COGT) stake by 56% in Q2 2026, selling an estimated $2.41M and leaving 53,129 shares worth $2.06M. The position accounts for 0.18% of the portfolio, ranked #174.

EAM Investors first reported a position in COGT in Q2 2022 and has held it in 5 quarters since. The position peaked at $5.04M in Q3 2022. 324 funds tracked by Wall St. Rank hold COGT as of Q2 2026.

  • EAM Investors held 53,129 shares of Cogent Biosciences worth $2.06M as of Q2 2026.
  • EAM Investors sold 68,799 Cogent Biosciences shares in Q2 2026, an estimated $2.41M.
  • Cogent Biosciences made up 0.18% of EAM Investors's portfolio in Q2 2026, its #174 holding.
  • EAM Investors first reported a position in Cogent Biosciences in Q2 2022 and has held it in 5 quarters since.
  • EAM Investors's Cogent Biosciences position peaked at $5.04M in Q3 2022.
  • 324 funds tracked by Wall St. Rank held Cogent Biosciences as of Q2 2026.

Based on EAM Investors's 13F filing for Q2 2026, filed 13 Aug 2026.